Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

• Main Authors: Poh, Xuan Ying, Lee, I. Russel, Lim, Clarissa, Teo, Jefanie, Rao, Suma, Chia, Po Ying, Ong, Sean W. X., Lee, Tau Hong, Lin, Ray J. H., Ng, Lisa F. P., Ren, Ee Chee, Lin, Raymond T. P., Wang, Lin-Fa, Renia, Laurent, Lye, David C., Young, Barnaby Edward
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2023
• Subjects: Science::Medicine; COVID-19; SARS-CoV-2
• Online Access: https://hdl.handle.net/10356/171102
• Institution: Nanyang Technological University

Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore, two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Programme for use as the primary vaccination series. More than 90% of the Singapore population has received at least one dose of a COVID-19 vaccine as of December 2021. With the demonstration that vaccine effectiveness wanes in the months after vaccination, and the emergence of Omicron which evades host immunity from prior infection and/or vaccination, attention in many countries has shifted to how best to maintain immunity through booster vaccinations.